Do analysts recommend DERM or LTRN?

Journey Medical presently has a consensus price target of $13.00, suggesting a potential upside of 105.05%. Given Journey Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Journey Medical is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Journey Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend NRXP or LTRN?

NRx Pharmaceuticals presently has a consensus price target of $38.25, indicating a potential upside of 896.09%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe NRx Pharmaceuticals is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NRXP or LTRN more profitable?

NRx Pharmaceuticals' return on equity of 0.00% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals N/A N/A -202.92% Lantern Pharma N/A -198.34% -129.08%

Do analysts rate IPHA or LTRN?

Innate Pharma presently has a consensus price target of $5.00, indicating a potential upside of 184.09%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Innate Pharma is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innate Pharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, IPHA or LTRN?

Lantern Pharma has lower revenue, but higher earnings than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $10.19M 16.22 -$55.64M N/A N/A Lantern Pharma N/A N/A -$17.12M -$1.45 N/A

Is IPHA or LTRN more profitable?

Innate Pharma's return on equity of 0.00% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Innate Pharma N/A N/A N/A Lantern Pharma N/A -198.34% -129.08%

Do analysts recommend LTRN or IFRX?

InflaRx has a consensus target price of $7.00, suggesting a potential upside of 337.50%. Given InflaRx's stronger consensus rating and higher probable upside, analysts plainly believe InflaRx is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 InflaRx 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Is LTRN or IFRX more profitable?

InflaRx's return on equity of -88.30% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -198.34% -129.08% InflaRx N/A -88.30% -65.77%

Do analysts prefer SPRO or LTRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Lantern Pharma (LTRN) Competitors

$3.88 -0.19 (-4.67%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$3.92 +0.04 (+1.11%)

As of 06/12/2026 07:58 PM Eastern

Compare

LTRN vs. DERM, NRXP, IPHA, IFRX, and SPRO

Should you buy Lantern Pharma stock or one of its competitors? MarketBeat compares Lantern Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lantern Pharma include Journey Medical (DERM), NRx Pharmaceuticals (NRXP), Innate Pharma (IPHA), InflaRx (IFRX), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry.

How does Lantern Pharma compare to Journey Medical?

Journey Medical (NASDAQ:DERM) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Journey Medical presently has a consensus price target of $13.00, suggesting a potential upside of 105.05%. Given Journey Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Journey Medical is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

7.3% of Journey Medical shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 15.0% of Journey Medical shares are held by company insiders. Comparatively, 8.5% of Lantern Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Journey Medical has higher revenue and earnings than Lantern Pharma. Journey Medical is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.82	-$11.43M	-$0.37	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

Lantern Pharma has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Journey Medical's return on equity of -35.57% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-14.82%	-35.57%	-10.88%
Lantern Pharma	N/A	-198.34%	-129.08%

In the previous week, Journey Medical had 2 more articles in the media than Lantern Pharma. MarketBeat recorded 3 mentions for Journey Medical and 1 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 1.87 beat Journey Medical's score of 0.94 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Journey Medical	Positive
Lantern Pharma	Very Positive

Journey Medical has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.33, meaning that its share price is 133% more volatile than the broader market.

Summary

Journey Medical beats Lantern Pharma on 10 of the 15 factors compared between the two stocks.

How does Lantern Pharma compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

NRx Pharmaceuticals has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.33, meaning that its share price is 133% more volatile than the broader market.

Lantern Pharma has lower revenue, but higher earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	113.11	-$28.62M	-$1.09	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, NRx Pharmaceuticals and NRx Pharmaceuticals both had 1 articles in the media. Lantern Pharma's average media sentiment score of 1.87 beat NRx Pharmaceuticals' score of 0.65 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
NRx Pharmaceuticals	Positive
Lantern Pharma	Very Positive

NRx Pharmaceuticals' return on equity of 0.00% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-202.92%
Lantern Pharma	N/A	-198.34%	-129.08%

NRx Pharmaceuticals presently has a consensus price target of $38.25, indicating a potential upside of 896.09%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe NRx Pharmaceuticals is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Lantern Pharma beats NRx Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Lantern Pharma compare to Innate Pharma?

Innate Pharma (NASDAQ:IPHA) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Lantern Pharma has lower revenue, but higher earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	16.22	-$55.64M	N/A	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

In the previous week, Innate Pharma and Innate Pharma both had 1 articles in the media. Innate Pharma's average media sentiment score of 1.89 beat Lantern Pharma's score of 1.87 indicating that Innate Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Innate Pharma	Very Positive
Lantern Pharma	Very Positive

Innate Pharma has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.33, meaning that its stock price is 133% more volatile than the broader market.

Innate Pharma's return on equity of 0.00% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Lantern Pharma	N/A	-198.34%	-129.08%

0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Innate Pharma presently has a consensus price target of $5.00, indicating a potential upside of 184.09%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Innate Pharma is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Innate Pharma beats Lantern Pharma on 9 of the 12 factors compared between the two stocks.

How does Lantern Pharma compare to InflaRx?

Lantern Pharma (NASDAQ:LTRN) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

InflaRx has a consensus target price of $7.00, suggesting a potential upside of 337.50%. Given InflaRx's stronger consensus rating and higher probable upside, analysts plainly believe InflaRx is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Lantern Pharma has higher earnings, but lower revenue than InflaRx. Lantern Pharma is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A
InflaRx	$30K	3,855.47	-$51.63M	-$0.71	N/A

Lantern Pharma has a beta of 2.33, suggesting that its share price is 133% more volatile than the broader market. Comparatively, InflaRx has a beta of 2.42, suggesting that its share price is 142% more volatile than the broader market.

In the previous week, InflaRx had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 2 mentions for InflaRx and 1 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 1.87 beat InflaRx's score of 1.79 indicating that Lantern Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Lantern Pharma	Very Positive
InflaRx	Very Positive

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by company insiders. Comparatively, 16.3% of InflaRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

InflaRx's return on equity of -88.30% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-198.34%	-129.08%
InflaRx	N/A	-88.30%	-65.77%

Summary

InflaRx beats Lantern Pharma on 13 of the 15 factors compared between the two stocks.

How does Lantern Pharma compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Spero Therapeutics has a net margin of 24.90% compared to Lantern Pharma's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
Lantern Pharma	N/A	-198.34%	-129.08%

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Spero Therapeutics has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	2.47	$8.57M	$0.24	11.88
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

In the previous week, Spero Therapeutics had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 1.87 beat Spero Therapeutics' score of 1.42 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Spero Therapeutics	Positive
Lantern Pharma	Very Positive

Spero Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.33, meaning that its share price is 133% more volatile than the broader market.

Summary

Spero Therapeutics beats Lantern Pharma on 9 of the 13 factors compared between the two stocks.

Get Lantern Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LTRN vs. The Competition

Export

Metric	Lantern Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$46.01M	$3.39B	$6.75B	$12.02B
Dividend Yield	N/A	2.25%	2.66%	5.61%
P/E Ratio	-2.68	19.48	24.05	24.42
Price / Sales	N/A	304.87	510.75	109.73
Price / Cash	N/A	124.89	44.01	55.64
Price / Book	6.69	8.32	10.66	6.79
Net Income	-$17.12M	$23.89M	$3.57B	$337.66M
7 Day Performance	8.08%	3.56%	0.88%	2.57%
1 Month Performance	54.58%	-1.29%	0.25%	2.04%
1 Year Performance	27.21%	44.89%	25.23%	30.28%

Lantern Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LTRN Lantern Pharma	1.5372 of 5 stars	$3.88 -4.7%	N/A	+20.1%	$46.01M	N/A	N/A	20	Positive News
DERM Journey Medical	2.4589 of 5 stars	$6.02 -1.1%	$13.00 +115.9%	-9.0%	$167.68M	$61.86M	N/A	90	Analyst Upgrade
NRXP NRx Pharmaceuticals	2.8227 of 5 stars	$4.60 -0.4%	$38.25 +731.0%	+11.6%	$167.38M	$1.23M	N/A	2	Gap Down
IPHA Innate Pharma	3.4878 of 5 stars	$1.82 +2.2%	$5.00 +174.7%	-11.1%	$167.18M	$10.19M	N/A	220	Positive News
IFRX InflaRx	2.9009 of 5 stars	$2.17 -4.8%	$7.00 +222.6%	+100.0%	$164.83M	$30K	N/A	60	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LTRN) was last updated on 6/13/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lantern Pharma (LTRN) Competitors

LTRN vs. DERM, NRXP, IPHA, IFRX, and SPRO

How does Lantern Pharma compare to Journey Medical?

Summary

How does Lantern Pharma compare to NRx Pharmaceuticals?

Summary

How does Lantern Pharma compare to Innate Pharma?

Summary

How does Lantern Pharma compare to InflaRx?

Summary

How does Lantern Pharma compare to Spero Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN vs. The Competition

Lantern Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lantern Pharma (LTRN) Competitors

LTRN vs. DERM, NRXP, IPHA, IFRX, and SPRO

How does Lantern Pharma compare to Journey Medical?

Do analysts recommend DERM or LTRN?

Do institutionals & insiders hold more shares of DERM or LTRN?

Which has stronger valuation and earnings, DERM or LTRN?

Is DERM or LTRN more profitable?

Does the media refer more to DERM or LTRN?

Which has more risk and volatility, DERM or LTRN?

Summary

How does Lantern Pharma compare to NRx Pharmaceuticals?

Which has more volatility & risk, NRXP or LTRN?

Which has stronger valuation and earnings, NRXP or LTRN?

Do insiders and institutionals have more ownership in NRXP or LTRN?

Does the media refer more to NRXP or LTRN?

Is NRXP or LTRN more profitable?

Do analysts recommend NRXP or LTRN?

Summary

How does Lantern Pharma compare to Innate Pharma?

Which has preferable valuation & earnings, IPHA or LTRN?

Does the media favor IPHA or LTRN?

Which has more risk and volatility, IPHA or LTRN?

Is IPHA or LTRN more profitable?

Do insiders and institutionals believe in IPHA or LTRN?

Do analysts rate IPHA or LTRN?

Summary

How does Lantern Pharma compare to InflaRx?

Do analysts recommend LTRN or IFRX?

Which has higher earnings & valuation, LTRN or IFRX?

Which has more volatility & risk, LTRN or IFRX?

Does the media favor LTRN or IFRX?

Do insiders and institutionals have more ownership in LTRN or IFRX?

Is LTRN or IFRX more profitable?

Summary

How does Lantern Pharma compare to Spero Therapeutics?

Is SPRO or LTRN more profitable?

Do institutionals & insiders believe in SPRO or LTRN?

Do analysts prefer SPRO or LTRN?

Which has higher earnings and valuation, SPRO or LTRN?

Does the media refer more to SPRO or LTRN?

Which has more risk and volatility, SPRO or LTRN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN vs. The Competition

Lantern Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools